Scholarlink

Objective <p>To investigate the expression and clinical significance of integrin subunit alpha 9 (ITGA9) and neuronal pentraxin 2 (NPTX2) in acute myeloid leukemia (AML), and to evaluate their potential diagnostic and prognostic value.</p> Methods <p>Differentially expressed genes (DEGs) associated with AML prognosis were identified from the Gene Expression Omnibus (GEO) dataset (GSE12417), followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The expression and prognostic relevance of candidate genes were further validated using The Cancer Genome Atlas (TCGA) dataset and the Xiantao Academic online platform. Correlations of ITGA9 and NPTX2 with immune-regulatory genes, immune checkpoint molecules, and immune cell infiltration were analyzed to explore their potential immune associations. Peripheral blood samples from 60 newly diagnosed AML patients and 50 healthy controls were collected for quantitative real-time PCR validation. Diagnostic and prognostic performances were assessed using receiver operating characteristic (ROC) curve and Kaplan–Meier survival analyses.</p> Results <p>Seven prognosis-related genes were identified, among which ITGA9 and NPTX2 were significantly upregulated in AML. ITGA9 and NPTX2 were predominantly involved in modulating signaling receptor functions and were primarily associated with the phosphatidylinositol 3-kinase–AKT (PI3K-Akt) signaling. Immune correlation analysis revealed that ITGA9 and NPTX2 were associated with multiple immune-regulatory and checkpoint molecules, indicating potential involvement in AML immune microenvironment modulation. Clinical validation confirmed that ITGA9 and NPTX2 were markedly overexpressed in the AML patients. ROC curve analysis demonstrated strong diagnostic efficacy for ITGA9 and NPTX2. Among the 60 AML patients followed up, 29 died, and the deceased group exhibited significantly higher ITGA9 and NPTX2 expression. High expression of ITGA9 and NPTX2 was associated with reduced relapse-free survival.</p> Conclusion <p>ITGA9 and NPTX2 are significantly overexpressed in AML and are closely associated with poor prognosis. Their strong diagnostic performance suggests that these two genes may serve as potential biomarkers and therapeutic targets for AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bioinformatics analysis and preliminary clinical validation of ITGA9 and NPTX2 as prognosis-related genes in acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Lili Chen,
  • Na Yang,
  • Fei Zhang,
  • Fang Lv,
  • Ningping Tan,
  • Yanan Zhang,
  • Guangqi Wu

摘要

Objective

To investigate the expression and clinical significance of integrin subunit alpha 9 (ITGA9) and neuronal pentraxin 2 (NPTX2) in acute myeloid leukemia (AML), and to evaluate their potential diagnostic and prognostic value.

Methods

Differentially expressed genes (DEGs) associated with AML prognosis were identified from the Gene Expression Omnibus (GEO) dataset (GSE12417), followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The expression and prognostic relevance of candidate genes were further validated using The Cancer Genome Atlas (TCGA) dataset and the Xiantao Academic online platform. Correlations of ITGA9 and NPTX2 with immune-regulatory genes, immune checkpoint molecules, and immune cell infiltration were analyzed to explore their potential immune associations. Peripheral blood samples from 60 newly diagnosed AML patients and 50 healthy controls were collected for quantitative real-time PCR validation. Diagnostic and prognostic performances were assessed using receiver operating characteristic (ROC) curve and Kaplan–Meier survival analyses.

Results

Seven prognosis-related genes were identified, among which ITGA9 and NPTX2 were significantly upregulated in AML. ITGA9 and NPTX2 were predominantly involved in modulating signaling receptor functions and were primarily associated with the phosphatidylinositol 3-kinase–AKT (PI3K-Akt) signaling. Immune correlation analysis revealed that ITGA9 and NPTX2 were associated with multiple immune-regulatory and checkpoint molecules, indicating potential involvement in AML immune microenvironment modulation. Clinical validation confirmed that ITGA9 and NPTX2 were markedly overexpressed in the AML patients. ROC curve analysis demonstrated strong diagnostic efficacy for ITGA9 and NPTX2. Among the 60 AML patients followed up, 29 died, and the deceased group exhibited significantly higher ITGA9 and NPTX2 expression. High expression of ITGA9 and NPTX2 was associated with reduced relapse-free survival.

Conclusion

ITGA9 and NPTX2 are significantly overexpressed in AML and are closely associated with poor prognosis. Their strong diagnostic performance suggests that these two genes may serve as potential biomarkers and therapeutic targets for AML.